Adverum Biotechnologies Inc. (NASDAQ: ADVM) stock closed at 1.51 per share at the end of the most recent trading day (a -1.95% change compared to the prior day closing price) with a volume of 388.06K shares and market capitalization of 149.14M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Adverum Biotechnologies Inc. CEO is Laurent Fischer.

The one-year performance of Adverum Biotechnologies Inc. stock is -37.4%, while year-to-date (YTD) performance is -14.2%. ADVM stock has a five-year performance of -40.78%. Its 52-week range is between 0.79535 and 2.57, which gives ADVM stock a 52-week price range ratio of 40.27%

Adverum Biotechnologies Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of 18.06, a price to cashflow ratio of 242.90, a PEG ratio of 2.32, a ROA of -36.77%, a ROC of -37.33% and a ROE of -45.95%. The company’s profit margin is -%, its EBITDA margin is -1 886.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Adverum Biotechnologies Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Adverum Biotechnologies Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Adverum Biotechnologies Inc. is Moderate Buy (1.67), with a target price of $3.5, which is +131.79% compared to the current price. The earnings rating for Adverum Biotechnologies Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adverum Biotechnologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adverum Biotechnologies Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.67, ATR14 : 0.13, CCI20 : -33.61, Chaikin Money Flow : -0.02, MACD : 0.04, Money Flow Index : 37.91, ROC : -0.65, RSI : 38.61, STOCH (14,3) : 60.00, STOCH RSI : 0.94, UO : 56.47, Williams %R : -40.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adverum Biotechnologies Inc. in the last 12-months were: Dawn A. Svoronos (Buy at a value of $25 578), James Scopa (Sold 50 000 shares of value $109 000 ), Julie Clark (Sold 4 766 shares of value $10 342 ), Kishor Peter Soparkar (Buy at a value of $24 994), Laurent Fischer (Buy at a value of $27 800), Peter Soparkar (Buy at a value of $24 994), Richard Beckman (Buy at a value of $8 228), Rupert D¿Souza (Buy at a value of $16 857), Setareh Seyedkazemi (Buy at a value of $16 800)